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ABSTRACT
Pre-eclampsia remains a major cause of poor perinatal outcome worldwide. As administering acetylsalicylic acid in a high 
risk population reduces the risk of PE, it is essential to identify women at risk of PE. Several algorithms for PE risk assessment 
have been developed. They include maternal factors combined with uterine artery pulsatility index, mean arterial pressure, 
serum pregnancy-associated plasma protein-A, placental growth factor, and serum soluble fms-like tyrosine kinase-1. Beside 
PE prophylaxis with acetylsalicylic acid, a proper management of women considered at a high risk of PE is essential. The 
sFlt-1:PlGF ratio between 20 and 34 + 6 weeks may be used to predict a short-term absence of PE or to predict the risk of 
PE diagnosis within 4 weeks and a significant shortening of the duration of pregnancy associated with it. The sFlt-1:PlGF 
ratio may be helpful in deciding about hospitalization or choosing the optimal time for corticosteroid administration in 
women at risk of PE. It may also help to reduce overall healthcare costs.
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INTRODUCTION
Hypertension affects about 6–8% of all pregnant women 
[1]. In Poland the estimated number of women suffering from 
hypertension during pregnancy is around 30,000 per year. Al-
though pre-eclampsia (PE) affects 2–3 % of patients, it carries 
a great risk of maternal and perinatal mortality and morbidity 
[1–3]. According to the World Health Report of 2005, 12% of all 
maternal deaths were related to eclampsia worldwide [4]. In 
the USA the rate of any pre-eclampsia or mild pre-eclampsia 
was quite constant over the last three decades. On the other 
hand, over a two-fold increase in severe PE occurrence was 
observed during that period [5] which puts such women at 
the highest risk of poor perinatal outcome. 
The results of the ASPRE Study were published in 
2017. According to the study, administering acetylsalicylic 
acid (ASA) since the first trimester of pregnancy in a high-
-risk population reduced the occurrence of PE < 34 weeks 
by 80% and < 37 weeks by 63% [6]. A recently published 
meta-analysis by Roberge et al. included sixteen trials on 
ASA in PE prevention with 18,907 participants. The main 
finding was that ASA reduced the risk of preterm PE when 
it was initiated at ≤ 16 weeks of gestation at a daily dose 
of ≥ 100 mg [7]. Nowadays ASA is widely recommended in 
PE prevention [8, 9]. Therefore, it is essential do correctly 
identify women at risk of PE to manage them with proper 
care in order to minimize the risks.
MATERNAL RISK FACTORS OF PE
According to the Regulation of the Minister of Health as 
of the 9th of November 2015 maternal risk factors of PE are: 
 Ū a history of severe PE and/or intrauterine growth 
restriction,
 Ū chronic hypertension,
 Ū chronic renal diseases,
 Ū pre-gravid diabetes mellitus,
 Ū body mass index (BMI) > 30,
 Ū autoimmune diseases (e.g. systemic lupus erythe-
matosus),
 Ū antiphospholipid syndrome or thrombophilia [8].
This list of risk factors is very similar to the one published 
by the American College of Obstetricians and Gynecologists 
(ACOG) in “Hypertension in Pregnancy” in 2013 [1]. ACOG 
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recommends qualifying women at a high risk of PE accor-
ding to the above mentioned risk factors and if they are 
over 40 years old, primiparous, in multiple pregnancy, after 
in-vitro fertilization procedure, or if their first-degree relative 
had a history of PE. The National Institute for Health and Care 
Excellence (NICE) published an overview on hypertension 
in pregnancy, which was last updated in 2017. According 
to this document two categories of risk factors of PE are 
distinguished. Women at a high risk of PE are those with 
hypertensive disease during the previous pregnancy, chro-
nic kidney diseases, autoimmune diseases such as systemic 
lupus erythematosus or antiphospholipid syndrome, type 
1 or type 2 diabetes or chronic hypertension. Primiparity, 
age > 40 years, pregnancy interval of > 10 years, pre-gravid 
BMI > 35, family history of PE and multiple pregnancy are 
considered to be moderate risk factors. The presence of two 
risk factors are considered equal to one high-risk factor [10]. 
Taking into account only the above mentioned maternal 
determinants results in the detection rate of PE of around 
40%. Wright et al. developed a model for the prediction 
of PE on the basis of maternal characteristics and medi-
cal history. 120,492 women were screened for PE between 
11 + 0 and 13 + 6 weeks of gestation. A total of 2,704 of 
them experienced PE in the further course of pregnancy 
(2.2%). The model including maternal characteristics and 
history predicted 40% of all PE cases, 48% of cases of PE 
requiring delivery < 37 weeks and 54% of cases of PE re-
quiring delivery < 34 weeks of gestation [11]. This leads to 
a conclusion that about 50–60% of pregnant women with 
PE have no possibility to have the risk factors determined 
in the first trimester of pregnancy. Estimating the risk of 
PE only on the basis of maternal and family history causes 
an underestimation of the number of women at risk of PE 
during the current pregnancy.   
ALGORITHMS OF PE PREDICTION
The utility of the predictive test depends on its sen-
sitivity, specificity but also the overall prevalence of the 
disease. The best way to assess the utility of the test is to 
analyze its likelihood ratio. Positive likelihood ratio (LR) is 
the proportion of patients with a condition who have po-
sitive test results to those without the condition who have 
identical test results. As PE is a rare condition, the screening 
test should have a high positive LR for adequate prediction 
of the probability of PE with low negative LR to exclude 
the disorder with confidence. A useful prediction test of 
PE would require a positive LR > 10 for a positive test and 
a negative LR < 0.2 for a negative test [1].
A model of PE prediction based on maternal characte-
ristics, biophysical and biochemical markers was published 
in 2016 by a group from King’s College in London. Maternal 
factors were combined with uterine artery pulsatility index 
(UTPI), mean arterial pressure (MAP), serum pregnancy-as-
sociated plasma protein-A (PAPP-A), and placental growth 
factor (PlGF) expressed as multiples of the median valu-
es. The test was applied in almost 36,000 of pregnant women 
between 11 + 0 and 13 + 6 gestational weeks, 2.9% of whom 
subsequently developed PE. Combining all the above men-
tioned factors allowed to detect 82% of PE requiring delivery 
at < 32 weeks (95% coefficient interval (CI) 70–90), 59% of 
PE requiring delivery between 32 + 0 and 36+6 weeks (95% 
CI 52–65), 37% of PE requiring delivery between 37 + 0 and 
39 + 6 weeks (95% CI 33–41) and 26% of PE requiring deli-
very beyond 40 weeks of gestation (95% CI 2132) at a 5% 
false positive rate. At false positive rate of 10% the detection 
rates are 89% (79–96), 71% (64–77), 54% (49–58) and 38% 
(32–44), respectively [12]. Different combinations of the 
above mentioned factors have lower detections rates. For 
example, taking into account maternal factors, MAP, UTPI 
and PAPP-A (without PlGF) allowed to detect 83% of all PE 
cases requiring delivery below 32 weeks of gestation (95% 
CI 72–91) with a 10% false positive rate [12]. 
Further algorithms of PE risk estimation during the 
second and third trimester of pregnancy have been de-
veloped. Gallo et al. presented a model of PE prediction 
between 19 and 24 gestational weeks. It included maternal 
factors, UTPI, MAP, PlGF and serum soluble fms-like tyrosine 
kinase-1 (sFlt-1) [2]. sFlt-1, also known as soluble vascular 
endothelial growth factor (VEGF) receptor 1 binds both cir-
culating VEGF and PlGF, thus decreasing their concentration 
in uteroplacental and maternal circulation [3]. In PE, circula-
ting maternal serum levels of sFlt-1 are increased, and PlGF 
levels are decreased [13, 14]. sFlt-1 causes vasoconstriction 
and endothelial damage that may lead to PE [15]. Importan-
tly, the increase in sFlt-1 and decrease in PlGF serum levels 
are ahead of the clinical symptoms of PE by 5 weeks [16]. 
The algorithm presented by Gallo et al. allowed to detect 
52%, 47%, and 37% of PE at < 32, < 37, and ≥ 37 weeks of 
gestation, respectively, at a false-positive rate of 10% [2]. 
Similar algorithms have been developed for PE predic-
tion at 30–34 weeks and 35–37 weeks of gestation. Predic-
ting 98% (95% CI 88–100) of preterm-PE and 49% (95% CI 
42–57) of term-PE at a false-positive rate of 5% [17] was 
possible with the implementation of the same factors as in 
the second trimester of pregnancy. The application of the 
algorithm to patients at 35–37 weeks of gestation predicted 
PE in 82% (95% CI 70–91) [18].  
Basing on the above mentioned studies Fetal Medicine 
Foundation developed a calculator for PE risk estimations, 
which is available online (https://fetalmedicine.org/rese-
arch/assess/preeclampsia). It allows to estimate the risk of 
PE using different algorithms in the first, second and third 
trimester of pregnancy. The questionnaire fields include all 
the risk factors used in the algorithm used for the specific 
337
Katarzyna Kosińska-Kaczyńska, Mirosław Wielgoś, Pre-eclampsia, prediction, PlGF, sFlt-1, risk factors
www. journals.viamedica.pl/ginekologia_polska
interval of pregnancy weeks. However, in case of the lack of 
any biomarkers, the calculator will use a different algorithm 
to calculate the risk of PE. The result is given with a comment 
qualifying it as low or high risk and with advice on further 
management.
A SHORT-TERM PREDICTION  
AND EXCLUSION OF PE
In 2016 the PROGNOSIS study on the predictive value of 
sFlt-1:PlGF ratio in women with suspected PE was published 
in the New England Journal of Medicine. A prospective mul-
ticenter observational research on 1,273 women between 
24 and 36 + 6 weeks of gestation with suspected PE was 
performed. sFlt-1:PlGF ratio of 38 or lower was predictive 
of the absence of PE within one week (negative predictive 
value 99.3%, 95% CI 97.9–99.9), with 80% sensitivity (95% 
CI 51.9–95.7) and 78.3% specificity (95% CI 74.6–81.7). The 
positive predictive value of sFlt-1:PlGF ratio at or above 
38 for a diagnosis of PE within 4 weeks was 36.7% (95% CI 
28.4–45.7), with 66.2% sensitivity (95% CI 54.0–77.0) and 
83.1% specificity (95% CI 79.4–86.3). In conclusion, the au-
thors stated that sFlt-1:PlGF ratio of 38 or lower may be 
used to predict the short-term absence of PE in women in 
whom the syndrome is clinically suspected [19]. Moreover, 
sFlt-1:PlGF ratio above 38 was associated with a significantly 
shorter time to delivery regardless of PE status [20]. If the test 
was applied between 24 and 33 + 6 gestational weeks and 
the results were ≥ 38, the likelihood of imminent delivery 
was 2.9 fold greater than if the test result was < 38. In women 
with sFlt-1:PlGF ratio exceeding 38 the time to delivery was 
also 38% shorter than in women with the test ratio of 38 or 
below. In 250 women with sFlt-1:PlGF ratio above 38 the 
mean time from the test to delivery was 17 days (interqu-
artile range 10–26 days) [20]. 
Recently, a meta-analysis and a systematic review of 
sFlt-1:PlGF ratio in the prediction of PE has been published 
in Hypertension by Agrawal et al. The meta-analysis consi-
sted of 15 studies, 8 of which included pregnant women at 
a high risk of PE and 7 at a low risk of PE (534 cases of PE 
and 19,587 controls). The pooled sensitivity of sFlt-1:PlGF 
ratio in predicting PE was 0.80 (95% CI 0.68–0.88) and the 
pooled specificity was 0.92 (95% CI 0.87–0.96). The positive 
LR was 10.5 (6.2–18) and negative LR 0.22 (0.13–0.35), which 
are very similar to the expected performance of a useful 
prediction test for PE [3]. Therefore, if the test is positive, 
the probability of having PE increases to 78%, while if the 
test is negative, it decreases to 7%. 
The presented performance of the test makes it useful in 
clinical practice. It allows a more accurate prediction of the 
onset of PE and better patient management. sFlt-1:PlGF ratio 
is helpful in deciding on follow-up and hospitalization of 
women at risk of PE and in deciding on the optimal time for 
corticosteroid administration in case of a high risk of preterm 
delivery [21]. The impact on budget by implying sFlt-1:PlGF 
ratio as a prediction test in women with suspected PE was 
analyzed in Italian population by Frusca et al. An economic 
model was developed to estimate the net financial impact 
on sFlt-1:PlGF ratio test in comparison with the current 
practice. A reduction in overall healthcare costs by 28% 
was observed. In particular, test implementation reduced 
69.5% of unnecessary hospitalizations [22]. A similar cost-
-effectiveness study of PE testing in UK was published. The 
use of sFlt-1:PlGF ratio test translated into saving £344 per 
a pregnant woman [23]. NICE has been recommending 
using sFlt-1:PlGF ratio in the management of women with 
symptoms of PE since 2016 [24]. The test should be used to 
rule out PE in women with suspected PE between 20 and 
34 + 6 weeks of gestation. 
Nowadays further studies on biochemical markers of 
PE and their usefulness in algorithms of PE prediction are 
conducted. A new model of prediction of delivery with PE 
within one week in singleton pregnancies from 24 weeks 
to 36 + 6 weeks of gestation in patients with suspected PE 
has been recently developed. It included sFlt-1/PlGF ratio, 
NT-proBNP and the gestational week at the time of the 
measurement. The addition of NT-proBNP improved the 
short-term prediction of delivery due to PE compared to 
sFlt-1/PlGF ratio alone [25]. Further prospective studies on 
a large population are necessary to estimate which biomar-
kers of PE have the highest utility in PE prediction.
CONCLUSIONS
PE remains one of the most important causes of mater-
nal and perinatal mortality and morbidity. It is well establi-
shed that ASA administered at a dose of > 100 mg before 
16 weeks of pregnancy reduces the risk of PE in a high risk 
population. Therefore, it is essential to identify women at 
risk of PE during the first trimester of pregnancy. Several 
algorithms for PE risk assessment have been developed and 
are available online. They include maternal factors combined 
with UTPI, MAP, PAPP-A, and PlGF expressed as multiples of 
the median values. Beside PE prophylaxis with ASA, a proper 
management of women considered to be at a high risk of PE 
is essential. sFlt-1:PlGF ratio between 20 and 34 + 6 weeks 
may be used to predict the short-term absence of PE in 
women in whom PE is clinically suspected or to predict the 
risk of PE diagnosis within 4 weeks and a significant shorte-
ning of duration of pregnancy associated with it. sFlt-1:PlGF 
ratio may be helpful in deciding about hospitalization or 
choosing the optimal time for corticosteroid administration 
in women at risk of PE. It may also help to reduce overall 
healthcare costs.
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